Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > duration

: 24 hours

or N/A (replacement)

& legal: [[USLegal:Prescription only|Rx-only]] in US

Use the filters below to narrow your results.

Allopurinol (1) · Amlodipine (1) · Anastrozole (1) · Benazepril (1) · Bimatoprost (1) · Dapagliflozin (1) · Doxazosin (1) · Empagliflozin (1) · Ezetimibe (1) · Fenofibrate (1) · Finasteride (1) · Fluconazole (1) · Glimepiride (1) · Irbesartan (1) · Latanoprost (1) · Linagliptin (1) · Lisinopril (1) · Losartan (1) · Lovastatin (1) · Methimazole (thiamazole) (1) · Mirabegron (1) · Olmesartan (medoxomil) (1) · Pravastatin (1) · Ramipril (1) · Rivaroxaban (1) · Rosuvastatin (1) · Sitagliptin (1) · Solifenacin (1) · Tamsulosin (1) · Telmisartan (1) · Terazosin (1) · Valsartan (1)

Altace (1) · Altoprev (ER), Mevacor (discontinued US); mostly generic (1) · Amaryl (1) · Arimidex (1) · Avapro (1) · Benicar (1) · Cardura, Cardura XL (1) · Cozaar (1) · Crestor, Ezallor (1) · Diflucan (1) · Diovan; Entresto (in fixed-dose combination with sacubitril) (1) · Farxiga (US), Forxiga (international) (1) · Flomax (1) · Hytrin (US brand discontinued); mostly generic (1) · Januvia; with metformin Janumet/Janumet XR (1) · Jardiance (1) · Lotensin (1) · Lumigan (glaucoma), Latisse (eyelash growth) (1) · Micardis (1) · Myrbetriq (1) · Norvasc, Katerzia (1) · Pravachol (1) · Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) · Tapazole; outside US Mercazole (1) · Tradjenta; with metformin Jentadueto (1) · Tricor, Lipofen, Antara, Fenoglide, Lofibra, Triglide, Trilipix (fenofibric acid) (1) · Vesicare (1) · Xalatan, Xelpros (1) · Xarelto (1) · Zestril, Prinivil, Qbrelis (1) · Zetia (1) · Zyloprim, Aloprim (IV) (1)

Other values:

0.4 mg PO once daily, 30 minutes after the same meal each day (1) · 1 drop in the affected eye(s) once daily in the evening (1) · 1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime (1) · 1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) · 1 mg PO once daily (1) · 1-2 mg PO once daily with breakfast; titrate by glycemic response (1) · 10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) · 10 mg PO once daily, with or without food (1) · 10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions) (1) · 10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4) (1) · 100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) · 150 mg PO once daily; titrate to 300 mg if needed (1) · 2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d (1) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · 20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) · 20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) · 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) · 40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) · 40 mg PO once daily; titrate to 80 mg (1) · 5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) · 5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) · 5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1) · 50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) · 80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID) (1) · IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1) · NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) · Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment (1) · Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)

0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle (1) · 0.01%, 0.03% ophthalmic solution (1) · 0.4 mg capsules (1) · 1 mg tablets (1) · 1 mg, 2 mg, 4 mg tablets (1) · 1 mg, 5 mg tablets (1) · 1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) · 1, 2, 5, 10 mg capsules and tablets (1) · 1.25, 2.5, 5, 10 mg capsules (1) · 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) · 10 mg, 20 mg, 40 mg, 80 mg tablets (1) · 10 mg, 25 mg tablets (1) · 10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets (1) · 100 mg, 300 mg tablets; IV 500 mg vial (1) · 2.5, 10, 15, 20 mg tablets (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · 2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) · 20, 40, 80 mg tablets (1) · 25 mg, 50 mg, 100 mg tablets (1) · 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · 40, 80, 160, 320 mg tablets; oral suspension (1) · 5 mg tablets; combination with metformin (1) · 5 mg, 10 mg tablets (1) · 5, 10 mg tablets (2) · 5, 10, 20, 40 mg tablets (2) · 5, 20, 40 mg tablets (1) · 50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) · 75, 150, 300 mg tablets (1) · Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg (1)

0.8 mg/d (rarely needed) (1) · 1 drop/eye/day (more frequent dosing reduces efficacy) (1) · 1 mg/d (1) · 10 mg/d (3) · 10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) (1) · 100 mg/d (2) · 16 mg/d (IR); 8 mg/d (XL) (1) · 20 mg/d (1) · 20 mg/d (hypertension); 10 mg/d (other indications typical) (1) · 25 mg/d (1) · 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d (1) · 300 mg/d (1) · 320 mg/d (hypertension); 320 mg/d (HF) (1) · 40 mg/d (1) · 40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg) (1) · 5 mg/d (2) · 50 mg/d (1) · 60 mg/d typical (1) · 8 mg/d (1) · 80 mg/d (4) · 80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1) · 800 mg/d (rarely needed) (1) · 800 mg/d (severe invasive disease) (1) · Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen) (1) · One drop per eye per day (1)

IV (2) · Oral (30) · Topical ophthalmic (2)

1-2 hours (1) · Biochemical improvement within 2-4 weeks; full euthyroid state 6-12 weeks (1) · BP and symptomatic LUTS improvement within 1-2 weeks (2) · BP effect 1-2 hours; max at 6 hours (1) · BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) · BP effect 1-2 weeks; max at 2-3 weeks (1) · BP effect 2 hours; max at 4-6 weeks (1) · BP effect within 1-2 weeks (2) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · BP lowering within 1 hour; max at 6 hours (1) · BP lowering within 1 hour; max effect at 6 hours (1) · BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) · Clinical improvement within 24-72 hours (1) · Estrogen suppression within days; clinical effect over months (1) · Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) · IOP lowering at 3-4 hours; maximum at 8-12 hours (1) · IOP lowering at 4 hours, maximum at 8-12 hours; eyelash effect after 2 months (1) · LDL lowering at 1 week, max by 4 weeks (1) · LDL lowering at 2 weeks, max by 4 weeks (2) · LDL lowering within 2 weeks (1) · Peak anticoagulant effect 2-4 hours (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (2) · Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation (1) · Symptom improvement within 1 week; peak effect at 4-6 weeks (1) · Symptom improvement within 1-2 weeks (1) · Symptom improvement within weeks (1) · Triglyceride lowering at 4-8 weeks (1)

25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) · 42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) · 60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) · 64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · <5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) · >90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1) · >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) · >90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) · High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) · High (oral; not significantly affected by food)'"`UNIQ--ref-00000B65-QINU`"' (1) · Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"' (1) · Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) · ~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) · ~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) · ~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"' (1) · ~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) · ~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' (1) · ~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) · ~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' (1) · ~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) · ~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1) · ~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1) · ~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1) · ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1) · ~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1) · ~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"' (1)